Zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma with specific gene alteration: a phase II study
{{output}}
Diffuse large B-cell lymphoma (DLBCL) remains clinically heterogeneous, and outcomes with R-CHOP are suboptimal in patients carrying high-risk genomic alterations such as MYD88, CD79B, NOTCH1, TP53 mutations or MYC rearrangements. Many of these lesions are ass... ...
